Aktie RXI PHARMACEUTICALS CORP
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen RXi Pharmaceuticals Corp OTC Bulletin Board

Aktien

US74979C1053

Schlusskurs OTC Bulletin Board
Andere Börsenplätze
- USD - Intraday Chart für RXi Pharmaceuticals Corp
02.07. Vorstand von Phio Pharmaceuticals genehmigt Aktiensplit im Verhältnis 1:9 MT
28.05. Phio Pharmaceuticals Corp. gibt positive Empfehlung des Sicherheitsüberwachungsausschusses der klinischen Studie der Phase 1b mit Phios Leitsubstanz PH-762 bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split
Phio Pharmaceuticals Announces Reverse Stock Split
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762
Phio Pharmaceuticals Corp. Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Phio Pharmaceuticals Files $100 Million Mixed Shelf
Phio Pharmaceuticals Secures New Investor
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A40GMU Aktie
  4. Aktie
  5. Nachrichten RXi Pharmaceuticals Corp
  6. Andere Sprachen